Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.82 |
| ▸ | ESR1 | P03372 | 13/20 | 0.82 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.82 |
| ▸ | TOP1 | P11387 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tallimustine SCHEMBL1230144 | 0.99 | HRAS (0.82) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL14102116 | 0.99 | HRAS (0.80) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL8193689 | 0.96 | HRAS (0.77) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL8193739 | 0.96 | HRAS (0.78) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7498611 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7501157 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7509817 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7506296 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7503106 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7504931 | 0.93 | HRAS (0.72) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7949 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-20230241057-A1 | COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI | UNIVERSITE PARIS 13 PARIS-NORD (FR) | 2023-08-03 | — | — | US | claimed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4157282-A1 | COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-05 | — | — | EP | claimed |
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| CN-1616099-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-1616098-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-05-18 | — | — | CN | claimed |
| US-20040259799-A1 | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia | ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIA (IT) | 2004-12-23 | — | — | US | claimed |
| WO-2004093856-A2 | COMBINATION OF A COX-2 INHIBITOR AND AN ALKYLATING-TYPE ANTINEOPLASTIC AGENT FOR TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-15 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| EP-0722446-B1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-12-11 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |